Great Ormond Street hoping to license gene therapy for ‘bubble baby’ syndrome
By Hannah Devlin,
The Guardian
| 05. 14. 2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success rate for treating the life-threatening disorder in which children have no immune system. But less than a year later, the therapy had been dropped by the pharmaceutical company that planned to bring it to market.
Now, Gosh is taking the unprecedented step of attempting to license the therapy itself on a non-profit basis and without industry involvement, in order to make it more widely available to babies and children worldwide.
“We’ve been developing the treatments, seeing the amazing results in trial and then we hit this roadblock,” said Prof Claire Booth, of Gosh and University College London, who was a principal investigator on the trial. “We’re seeing more and more companies pulling out of the field. So we needed to find a way to get it to patients.”
The move comes amid concern about the affordability of gene therapies...
Related Articles
By Anumita Kaur [cites CGS’ Katie Hasson], The Washington Post | 03.25.2025
Genetic information company 23andMe has said that it is headed to bankruptcy court, raising questions for what happens to the DNA shared by millions of people with the company via saliva test kits.
Sunday’s announcement clears the way for a new...
By Peter Wehling, Tino Plümecke, and Isabelle Bartram
| 03.26.2025
This article was originally published as “Soziogenomik und polygene Scores” in issue 272 (February 2025) of the German-language journal Gen-ethischer Informationsdienst (GID); translated by the authors.
In mid-November 2024, the British organization Hope not Hate published its investigative research ‘Inside the Eugenics Revival’. In addition to documentating an active international “race research” network, the investigation also brought to light the existence of a US start-up that offers eugenic embryo selection. Heliospect Genomics aims to enable wealthy couples to...
By Frank Landymore, Futurism | 03.18.2025
You can only throw so much money at a problem.
This, more or less, is the line being taken by AI researchers in a recent survey. Asked whether "scaling up" current AI approaches could lead to achieving artificial general...
By Craig S. Smith, Forbes | 03.08.2025
One recent evening in Shenzhen, a group of software engineers gathered in a dimly lit co-working space, furiously typing as they monitored the performance of a new AI system. The air was electric, thick with the hum of servers and...